相关实验视频
Updated: Feb 28, 2026

10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
10.0K
针对TRPA1使用基于不同支架的新型合成化合物来减少急性和慢性疼痛
Alessia Agata Corallo1, Samuele Maramai1, Carlotta Noli1
1Department of Biotechnology, Chemistry and Pharmacy, Università di Siena, Via A. Moro 2, 53100 Siena, Italy.
International journal of molecular sciences
|February 27, 2026
概括
研究人员探索了δ-sanshool衍生物来调节暂时受体潜在氨酸1 (TRPA1) 通道以缓解疼痛. 两种新型化合物在体内显示出有前途的止痛作用,突出了它们在疼痛管理中的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 短暂受体潜在氨酸1 (TRPA1) 通道参与疼痛信号传递.
- TRPA1是治疗急性和慢性疼痛的潜在治疗点.
研究的目的:
- 设计和合成基于自然化合物 δ-sanshool 的新型TRPA1调节器.
- 评估这些衍生品作为潜在止痛药的体外和体内疗效.
主要方法:
- 一个库的合成 δ-sanshool衍生物与各种胺头和不和链长度的库.
- 对TRPA1调节的化合物的体外试验.
- 分子对接以合理化实验结果.
- 在形式素诱导的可感应反应模型中的体内评估.
主要成果:
- 成功合成了新的δ-sanshool衍生物.
- 鉴定了两种在TRPA1.1处具有激素活性的化合物.
- 在体内疼痛模型中证明这些化合物的有希望的止痛特性.
结论:
- δ-sanshool衍生物代表了一个有前途的TRPA1调节器类.
- 合成的化合物具有开发新的疼痛治疗药物的潜力.
- 对于疼痛管理策略,需要对这些衍生品进行进一步的研究.
相关概念视频
Analgesia and Pain Management
2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
Opioid Receptors: Overview
5.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.4K
Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51

